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I. Introduction 
Direct-to-Consumer (“DTC”) genetic testing raises a set of concerns involving inadequate 
safeguards of test results to protect against the potential negative impact on personal privacy. The 
concerns arise from insufficient federal and state laws. In a technology-driven society, the prospect 
of data breaches releasing highly sensitive genetic information requires greater governmental 
oversight. This article explores the question of whether DTC genetic testing, specifically testing 
companies, should be subject to privacy requirements. An assessment of this issue requires first, 
an explanation of DNA testing technology, second, an analysis of the current privacy frameworks 
applicable to genetic testing, third, an assessment of the gaps in these frameworks, and last, 
consideration of mechanisms to maintain individual autonomy and privacy.   
II. DNA Testing Technology 
 A “genetic test” is defined as “an analysis of human DNA, RNA, chromosomes, proteins, 
or metabolites that detects genotypes, mutations, or chromosomal changes.”1 The evaluation of 
DNA testing technology begins with a brief description of the molecular analysis techniques 
followed by an in-depth analysis of DTC genetic tests (“DTC-GT”) and genetic testing companies.  
 
1 74 Fed. Reg. 51701. 
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A. Science of Genetic Testing 
 Genetic testing may be useful for determining paternity, matching forensic tissue, assessing 
ancestry, and identifying genetic predispositions to specific diseases or reproductive risks. DTC 
tests designed to identify genealogy or predisposition to disease are done by molecular techniques 
such as polymerase chain reaction (“PCR”), and next-generation sequencing (either whole-exome 
or whole-genome sequencing).2  
1. The DNA Molecule 
The Human Genome Project, started by the National Institute of Health (“NIH”) in 1990, 
was designed to “decipher the massive amount of information contained in our genome – the DNA 
(deoxyribonucleic acid) found within all our chromosomes.”3 DNA is the molecule of life that 
makes up the chemical subunits of human chromosomes.4 A gene is the unit of heredity passed 
from parent to offspring that affects traits/characteristics of an individual.5 The primary purpose 
of DNA is to encode the information necessary in proteins for cell structure and function.6 A cell 
synthesizes the proteins by a process known as gene expression in which a gene sequence affects 
the characteristics of the cell.7 An individual’s gene sequence leads to the expression of 
morphological, physiological, and behavioral traits.8 An alternate version of a specific gene known 
as an allele can account for the differences in traits as each allele encodes a particular protein 
 
2 ROBERT J. BROOKER, GENETICS ANALYSIS & PRINCIPLES 616 (5th ed. 2015). [hereinafter Genetic 
Analysis]. 
3 Id. at 1.   
4 Id. at 2.  
5 Id. at 4.  
6 Id. at 5.  
7 Id. at 6.  
8 Id. at 6-7. 
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function or expression.9 These inherited differences in characteristics due to genetic variation10 
make genetic tests useful.  
2. Polymerase Chain Reaction (“PCR”) Testing 
 Molecular markers11 are useful in polymerase chain reactions and gel electrophoresis.12 
PCR amplifies the gene from a sample of cells by separating the DNA strands with high 
temperature leaving two free single-stranded DNA molecules.13 As the temperature lowers, 
primers made of short single-stranded DNA bind to specific sites in the template DNA, each 
binding near one end of the gene of interest.14 Once the primers bind, the temperature is raised 
slightly, and a polymerase enzyme is added to the reaction to synthesize a strand of DNA 
complementary to the single-stranded template DNA.15 The third step, known as primer extension 
results in double the amount of template DNA.16 The three-step process of PCR can be repeated 
for as many cycles as necessary. A typical PCR run can take a couple of hours.17  
 Once the template DNA sequence has been amplified, it may be tested for the presence of 
the sequence by running either (1) the sample on a gel stained with ethidium bromide and 
observing if the gel fluoresces under UV light or (2) with real-time PCR.18 Scientists can determine 
the amount of the specific product as the PCR runs by adding a probe that emits fluorescence at a 
particular wavelength.19 If a fluorescent band of the correct size or the level of the fluorescence 
 
9 Id. at 7. 
10 Id. at 186. 
11 A molecular marker is a segment of DNA at a specific site along a chromosome. The markers may vary among 
individuals. Geneticists use the markers as references to determine patterns of genetic variations. See id. at 557t.  
12 Id. at 506. 
13 Id. at 505, 616. 
14 Id.  
15 Id. at 506. 
16 Id.  
17 Id.  
18 Id.  
19 Id.  
4
Health Law Outlook, Vol. 11 [2020], Iss. 1, Art. 2
https://scholarship.shu.edu/health-law-outlook/vol11/iss1/2
Missel 4 
 
from the probe increases, it indicates a successful amplification.20 However, even with multiple 
PCR amplification cycles, next-generation sequencing continues to be the preferred method of 
genetic analysis because it can detect all variants and mutations.  
3. Next-Generation Sequencing (“NGS”) 
Genotyping deals with differences in an individual’s genetic makeup compared to another 
individual and looks at genetic variation among populations.21 Whole-exome and whole-genome 
sequencing (next-generation sequencing) involves sequencing the individual’s entire DNA as 
opposed to a gene of interest in PCR testing. Whole-exome sequencing examines the exons within 
the gene.22 Exons are a portion of the genome that provides instructions for making proteins.23 
Whole-exome sequencing identifies variations in the protein-coding region of any gene, which is 
efficient in identifying possible disease-causing mutations.24 However, whole-exome sequencing 
misses DNA variations that occur outside the exons but still affect gene activity.25 Whole-genome 
sequencing can detect differences in any part of the genome and determines the order of all the 
nucleotides in an individual’s DNA.26  
4. Single Nucleotide Polymorphisms (“SNPs”) 
 An even cheaper approach to DNA sequencing is to examine SNPs. A SNP is a site in the 
genome where one of the nucleotide bases (A, T, G, or C) occurs in several different forms among 
different individuals.27 The common sites on the genome are used in the mapping of genes and 
 
20 Id. 
21 Id.  
22 DEP’T. OF HEALTH & HUMAN SERVS. NAT’L INST. OF HEALTH, NAT’L CTR. FOR BIOMEDICAL 
COMMC’N, HELP ME UNDERSTAND GENETICS: GENETIC TESTING (2019), https://ghr.nlm.nih.gov/ 
[hereinafter Genetic Testing].  
23 Genetic Testing, supra note 22, § Next-Generation Sequencing. 
24 Id. 
25 Id. 
26 Id. 
27 Genetic Analysis, supra note 2, at 557t. 
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disease-causing alleles during genetic testing as they involve a large number of variations.28 
Scientists use SNPs to estimate a person’s ethnic background for ancestry tests and have identified 
more than one million SNPs, which correspond to clinical and non-clinical traits.29  
B. What is a Direct-to-Consumer (“DTC”) Genetic Test? 
 DTC genetic testing provides individuals with direct access to their genetic information 
without involving a healthcare provider or insurance company. Individuals can buy the tests online 
or in stores and submit a DNA sample to the company by mail.30 Customers receive their results 
directly from a secure website or in a written report.31 There are various kinds of DTC-GTs 
available: ancestry or genealogy, disease risk and health, kinship, and lifestyle.32  
1. Genetic Ancestry Testing 
 Genetic ancestry testing or genealogy testing uses DNA variations from SNPs to provide 
an estimate of ethnic background.33 Genetic modification is often shared between people from 
similar backgrounds. 34 Genealogy tests can be used in population genetics to study how people 
migrated and mixed with other ethnic groups.35 However, ancestry tests are limited because test 
results are compared to different databases to identify shared molecular markers.36 
 
28 Id. 
29 Genetic Testing, supra note 22, § DTC Overview; see generally Alain Vignal et al., A Review on SNP and Other 
Types of Molecular Markers and Their Use in Animal Genetics, 34 GENETICS SELECTION EVOLUTION 275, 
277-78 (2002).  
30 Genetic Testing, supra note 22, § DTC Overview. 
31 Id. 
32 Id. 
33 Id. 
34 Id. 
35 Id. 
36 Id. 
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2. Disease Risk and Health 
Disease risk and health-based genetic tests estimate an individual’s genetic risk of 
developing common diseases/disorders.37 These tests may also identify if an individual is a gene 
carrier for a specific genetic variation/mutation.38 A genetic carrier inherits a recessive39 allele for 
the genetic trait/mutation but does not display the symptoms of the disease or trait.40 Carriers can 
pass the recessive allele on to their offspring, and if the offspring acquires another recessive allele 
from the other parent, the offspring will express the genetic trait/mutation and its symptoms.41 
 Lifestyle tests are a form of disease risk and health-based tests as they inform the consumer 
how DNA variations may impact lifestyle factors, e.g., fitness, weight loss, nutrition, and sleep.42 
Results are based on an analysis of genetic mutations “that are known or suspected to be associated 
with the disease or trait.”43 
C. Direct-to-Consumer Genetic Testing Companies 
Direct-to-consumer genetic testing companies (“DTC-GTC’s”) gained prominence with 
the sequencing of the human genome. These companies provide genome sequencing services 
directly to the consumer. DTC genetic testing currently has very little regulation or oversight.44 
 
37 Id. 
38 Id. 
39 “Variant masked by the presence of dominant traits but reappears in subsequent generations.” See Genetic Analysis, 
supra note 2, at 23. 
40 Id. at 31-2. 
41 Id. 
42 Id. 
43 Genetic Testing, supra note 22, § DTC Overview. 
44 James W. Hazel et al., Who Knows What, and When?: A Survey of the Privacy Policies Proffered by U.S. Direct-
to-Consumer Genetic Testing Companies, 28 CORNELL J. OF LAW AND PUB. POL’Y 35, 48-50 (2018). 
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1. Overview of Companies’ Policies  
The majority of genetic testing companies have privacy policies or terms of services 
accessible on their websites.45 However, some of these policies only apply to the use of the 
company’s website and not the specific test kit and genetic information.46 Some companies only 
provide additional consent requirements for participation in third-party research.47 Out of thirty 
companies' marketing test kits, most companies failed to “consistently meet international 
transparency guidelines related to confidentiality, privacy, and secondary use of data.”48 
2. Companies’ use of Genetic Data  
Genetic testing companies sometimes share information with pharmaceutical companies. 
For instance, 23andMe sells customers’ genetic data to GlaxoSmithKline to translate genetic and 
phenotypic data into targeted pharmaceutical treatments for Parkinson’s disease.49 Other 
companies share customer data only on an opt-in basis.50 More than 75 percent of customers agree 
to participate in the sharing of their data for research in determining disease risk.51 Although most 
testing companies only share de-identified data after receiving explicit consent from the consumer, 
some websites allow people to upload genetic information and search for relatives.52  
 
45 Id. 
46 Id.  
47 Id.  
48 Linnea I. Laestadius et al., All Your Data (Effectively) Belong to Us: Data Practices Among Direct-to-Consumer 
Genetic Testing Firms, 19 GENETICS IN MED. 513, 513 (2017). 
49 Press Release, GlaxoSmithKline, GSK and 23andMe Sign Agreement to Leverage Genetic Insights for the 
Development of Novel Medicines (July 25, 2018) https://www.gsk.com/en-gb/media/press-releases/gsk-and-
23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/. [hereinafter GSK].  
50 Julian Segert, UNDERSTANDING OWNERSHIP AND PRIVACY OF GENETIC DATA, Harvard University The 
Graduate School of Arts and Sciences (2018) http://sitn.hms.harvard.edu/flash/2018/understanding-ownership-
privacy-genetic-data/. 
51 Id.  
52 Id.  
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GEDMatch’s public upload websites helped law enforcement solve the Golden State Killer 
cold case.53 Following the Golden State Killer identification, GEDMatch updated its privacy 
policy to state that genetic data from GEDMatch could be freely used by law enforcement.54 
Conversely, 23andMe and Ancestry require court orders or valid search warrants before 
giving third parties or law enforcement access to genetic data records.55 However, these policies 
do not guarantee relatives of the individual any protection from future lawful use. As mentioned 
above in ancestry testing, family members share portions of their genome. So even though the 
relative does not upload or consent for their genetic information to be shared and utilized, their 
heritage can still be identified as well as the possibility of identifying disease risk. With the nature 
of the human genome being individually unique, de-identified information may still allow people 
to connect the data back to the original person.56 
III. Genetic Testing Privacy Frameworks  
 Genetic privacy may be compromised if testing companies remain unregulated and use 
genetic information in an unauthorized way. Federal and State governments’ privacy laws 
 
53 Linnea M Baudhuin et al, Privacy In Direct-To-Consumer Genetic Testing, 65 CLINICAL CHEMISTRY 612, 612-
17 (2019) (The police were unable to detect a match through CODIS, so they turned to GEDMatch, a database of 
genetic information from approximately 900,000 users who have voluntarily uploaded their genetic data after being 
tested by DTC-GTCs. Through GEDMatch, police were able to trace the serial killer to his great-great-great 
grandparents and then months later were able to find a branch of the family tree that hailed from the western United 
States.) 
54 Id.  
55 Id.  
56 Id. DTC genetic testing consumers need to realize that publicly sharing their data allows anyone access to their 
genetic data, and, by default, they place their family members at privacy risk as well. Consumers assume they will be 
anonymous; however, researchers have proven that they can rapidly re-identify DTC genetic consumers based on their 
genetic test results. Consumer re-identification can reveal very sensitive medical information about the donor and even 
about that person's relatives (particularly if, for example, information about mitochondrial DNA or the Y chromosome 
is included). It may also be used to connect the donor or a relative to another known DTC genetic consumer; see also 
Yaniv Erlich et al., Identity Inference Of Genomic Data Using Long-Range Familial Searches, 362 SCIENCE 690, 
690-94 (2018); see also Muhammad Naveed et al. Privacy in the Genomic Era, 48 ACM COMPUT. SURV. 48 (2015); 
see also Erika Check Hayden, The Genome Hacker, 497 NATURE 173 (2013); see generally Zhen Lin et al., Genetics, 
Genomic Research & Human Subject Privacy, 305 SCIENCE 183, 183 (2004).   
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designed to protect consumers’ right to privacy vary in terms of their breadth and do not extend to 
DTC-GTs.57 Likewise, genetic testing companies’ privacy policies range in their 
comprehensiveness of the public’s privacy concerns.58   
A. Federal Privacy Laws 
1. The Fourth Amendment - Searches of DNA Databases by the Government  
The Fourth Amendment protects an individual’s privacy interest from unreasonable 
searches and seizures:  
“The right of the people to be secure in their persons, houses, papers, and effects 
against unreasonable searches and seizures, shall not be violated, and no Warrants 
shall issue, but upon probable cause, to be supported by Oath or Affirmation and 
particularly describing the place to be searched, and the persons or things to be 
seized.”59 
 In Maryland v. King, the Supreme Court found acceptable genetic searches for individuals 
with diminished expectations of privacy.60 A lawful arrest based on probable cause for a “serious” 
crime permits the police to collect a DNA sample via a cheek swab for identification purposes 
because it is minimally intrusive.61 Conducting a DNA test as part of an arrest procedure does not 
violate the Fourth Amendment’s protections because it serves legitimate state interests.62  
The Fourth Amendment’s protections against searches and seizures generally do not apply 
to genetic information that is voluntarily shared, e.g., with a third party through DTC-GTs. In 
United States v. Miller, the Supreme Court ruled that voluntary data sharing negates expectations 
 
57 JOHN HOPKINS UNIV., GENETICS & PUB. POL’Y CTR,  SURVEY OF DIRECT-TO-CONSUMER TESTING 
STATUTES AND REGULATIONS (2007) [hereinafter Survey of DTC Statutes and Regulations]; See, e.g., Kayte 
Spector-Bagdady & Elizabeth R. Pike, Consuming Genomics: Regulating Direct-to-Consumer Genetic and Genomic 
Information, 92 NEB. L. REV. 677, 697 (2014). 
58 Id.  
59 U.S. CONST. Amend IV.  
60 Maryland v. King, 133 S. Ct. 1958 (2013).  
61 Id.  
62 Id.  
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of privacy.63 This rule denies Fourth Amendment protections under the circumstances described 
above in which DTC genetic test results are openly shared through public upload websites. In these 
instances, the government does not need to secure a warrant before searching the site for relevant 
genetic information.    
2. Health Information Portability and Accountability Act (“HIPAA”)  
 The HIPAA privacy rule only applies to protected health information of covered entities 
and their business associates.64 The privacy rule protects all “individually identifiable health 
information” held or transmitted by a covered entity or its business associate, in any form of media, 
whether electronic, paper, or oral.65 The privacy rule calls this information “protected health 
information” or “PHI.” HIPAA applies to HIPAA covered entities, including a health care 
provider, a health plan or a health care clearinghouse.66 Under HIPAA, genetic information is 
considered health information, and covered entities are prohibited from using and disclosing 
genetic information for underwriting purposes.67 DTC-GTC’s transmit information electronically, 
but they are not doctors, clinics, psychologists, dentists, chiropractors, nursing homes, nor 
pharmacies. DTC-GTs are not covered under HIPAA. Even though genetic tests contain 
individually identifiable health information this type of information is not protected.   
Under HIPAA, a business associate is an entity that performs certain functions or activities 
on behalf of or provides certain services to, a covered entity that involves the use or disclosure of 
individually identifiable health information.68 However, the Act does not consider persons or 
 
63 United States v. Miller, 425 U.S. 435 (1976) (finding defendant had no legitimate expectation of privacy in his bank 
records because the bank was a third party to which he disclosed his affairs when he opened his account.)  
64 See Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 110-233, 122 Stat. 881 (May 21, 
2008) Title I, § 105(a); 42 U.S.C.A. § 1320d-9. [hereinafter HIPAA]. 
65 Id.  
66 Id 
67 Id.  
68 Id. 
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organizations business associates if their functions or services do not involve the use or disclosure 
of protected health information.69  DTC-GTC’s are not business associates because they do not 
perform functions or activities on behalf of a covered entity. However, if the company is providing 
services on behalf of a physician, the tests are not DTCs but instead physician-ordered genetic 
tests and subject to HIPAA.  
3. Genetic Information Nondiscrimination Act (“GINA”)  
President Bush signed into law the Genetic Information Nondiscrimination Act on May 21, 
2008.70 Under GINA, genetic information is defined as “any individual, information about (1) such 
individual’s genetic tests, (2) the genetic tests of family members of such individual, and (3) the 
manifestation of a disease or disorder in family members of such individual.”71 GINA is notable 
in that it prohibits health insurers from engaging in genetic discrimination and regulates the release 
of genetic information and employer’s requirement of genetic testing.72 GINA prevents health 
insurers from increasing premiums or denying coverage to individuals based on genetic 
information.73 However, GINA does not apply to life, disability, or long-term care insurance.74 If 
DTC-GTC’s choose, they can release test results to insurers not covered under GINA upon their 
request.75 GINA also does not apply to law enforcement’s use of DTC genetic data.76  
 
69 Id. 
70 See Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff (2008) [hereinafter GINA]. 
71 Id. 
72 78 Fed. Reg 5658 (January 25, 2013).  
73 Id. 
74 Id.  
75 Id. 
76 Id. 
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4. Food and Drug Administration (“FDA”) 
The FDA classifies DTC-GTs as lower-risk medical devices subjected to the FDA’s 
“regulatory purview.”77 Currently, the FDA regulates a test kit based on how it comes to the 
market, i.e., a commercial test kit or a laboratory-developed test (LDT).78 On the one hand, a 
commercial marketed test kit processes genetic samples packaged together and sold to multiple 
laboratories.79 On the other hand, an LDT test kit is developed, performed, and sent to a single 
laboratory.80 The FDA chooses not to regulate LDTs for clinical or analytical validity because 
physicians order the tests.81  
Generally, the FDA does not review DTC tests for non-medical, low-risk medical, or 
general wellness purposes.82 The FDA evaluates moderate and high-risk tests before they can be 
offered to individuals to assess the tests' analytical and clinical validity.83 Carrier screening tests 
that determine whether an individual carries a genetic variant that can be passed down to offspring 
are exempt from FDA premarket review.84 Genetic tests intended to provide information about 
 
77 NAT’L INST. OF HEALTH, NAT’L HUMAN GENOME INST., REGULATION OF GENETIC TESTS (2018) 
genome.gov/about-genomics/policy-issues/Regulation-of-Genetic-Tests. [hereinafter Regulation of Genetic Tests]. 
78 Id.  
79 Id.  
80 Id.  
81 Id.  
82 FOOD & DRUG ADMIN. DIRECT-TO-CONSUMER TESTS, MEDICAL DEVICES: IN VITRO 
DIAGNOSTICS https://www.fda.gov/medical-devices/vitro-diagnostics/direct-consumer-tests.  
83 Id.; The FDA authorized 23andMe to offer a direct-to-consumer carrier status test for Bloom Syndrome in February 
2015, subsequently authorized it to carry out Genetic Health Risk (GHR) tests for ten diseases in April 2017, and 
mostly recently, authorized a test that reports on three mutations in BRCA genes in March 2018. As part of the pre-
market approval process for GHR tests, 23andMe was required to demonstrate the analytical validity of their tests as 
well as adequate consumer understanding of the sample collection process and the resulting genetic reports. Going 
forward, the FDA “intends to exempt additional 23andMe GHR tests from the FDA’s premarket review, and GHR 
tests from other makers may be exempt after submitting their first premarket notification . . . allow[ing] other, similar 
tests to enter the market as quickly as possible and in the least burdensome way, after a one-time FDA review.” Press 
Release, Fed. Drug Admin., FDA Allows Marketing of First Direct-to-Consumer Tests that Provide Genetic Risk 
Information for Certain Conditions (April 6, 2017), https://www.fda.gov/NewsEvents/Newsroom/ 
PressAnnouncements/ucm551185.htm; See also Press Release, Fed. Drug. Admin., FDA Permits Marketing of First 
Direct-to-Consumer Genetic Carrier Test for Bloom Syndrome (Feb. 23, 2015), https://www.fda 
.gov/newsevents/newsroom/pressannouncements/ucm435003.htm.  
84 21 CFR 866.5940.  
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specific medical conditions or diseases, and tests designed to provide information explaining 
medication side effects and genetic interaction are required to obtain FDA clearance before DTC-
GTCs can offer the tests.85  
5. Clinical Laboratory Improvement Act (“CLIA”) 
 The FDA and the Centers for Medicare and Medicaid Services (“CMS”) have the authority 
to regulate genetic tests.86 However, CMS regulation only extends to the analytical validity87 of 
the tests, not to the protection of individual private information.88 CMS regulates clinical 
laboratories through CLIA, which establishes a certification process for laboratories to process 
medical samples.89 While CLIA determines clinical testing quality, including verifying the 
procedures used, it does not examine whether tests are clinically valid or whether safeguards are 
in place to protect individual privacy.90 
 Laboratories' compliance with CLIA depends on the nature and complexity of the tests 
performed. CLIA classifies most genetic tests as moderate or high-complexity laboratory tests.91 
Laboratories that only perform tests that are simple laboratory examinations and procedures that 
pose no reasonable risk of harm if performed incorrectly may qualify for a certificate of waiver.92 
Moderate and high-complexity tests require a certificate of compliance by CMS.93 Laboratories 
 
85 21 CFR 866.5950; 21 CFR 862.3364. 
86 Regulation of Genetic Tests, supra note 77.  
87 Id. Analytical validity refers to how well the test predicts a genetic change. 
88 Id.  
89 Id. 
90 Id. 
91 NAT’L INST. OF HEALTH, NAT’L HUMAN GENOME INST., THE CLIA FRAMEWORK, (2018) 
https://www.genome.gov/Pages/PolicyEthics/GeneticTesting/The_CLIA_Framework.pdf. [hereinafter CLIA 
Framework].  
92 42 CFR 493.15. 
93 CLIA Framework, supra note 91.  
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that perform genetic tests have the option to either go through a proficiency testing program or 
evaluate their testing programs at least twice a year.94 
Clinical laboratories that comply with CLIA may release information “for the diagnosis, 
prevention, or treatment of any disease or impairment of, or the assessment of the health of, human 
beings.”95 Laboratories are exempt from CLIA requirements if they are “research laboratories that 
test human specimens but do not report patient-specific results for the diagnosis, prevention or 
treatment of any disease or impairment of, or the assessment of the health of individual patients.”96  
Here, DTC-GTCs do not need to comply with CLIA because they communicate test results 
to consumers, not for the diagnosis, prevention, or treatment of any disease or impairment. DTC-
GTCs purpose is for consumers to obtain information related to ancestry, risk of disease, and non-
clinical traits (hair color, earlobe type). LDTs, as discussed above, would need to comply with 
CLIA requirements as they are moderate or high complexity tests.  
6. Federal Trade Commission (“FTC”) Privacy Protection Laws  
 The FTC recommends that consumers scrutinize the company’s website and privacy 
practices regarding how genomic data is used, stored, and disclosed before buying a test kit.97 
Although the FTC does not provide genetic privacy protection, it can take action against companies 
that do not safeguard consumers' personal data.98 The FTC also has broad authority to police unfair 
 
94 CLIA Framework, supra note 91. See also 42 CFR 493.801(2)(ii). 
95 42 U.S.C. 263a. 
96 42 CFR 493.3(2). 
97 U.S. FED. TRADE COMM’N, DIRECT-TO-CONSUMER GENETIC TESTS, (2018); See also U.S. FED. TRADE 
COMM’N, DNA TEST KITS: CONSIDER THE PRIVACY IMPLICATIONS, (2017). 
98 See generally LabMD v. FTC, 1:14-cv-00810-WSD (11th Cir. 2019) (LabMD engaged in unreasonable data security 
practices that resulted in the unauthorized sharing of sensitive medical information. FTC concluded privacy harm is a 
substantial injury to consumers and LabMD must establish a comprehensive information security program subject to 
assessments); see also Press Release, U.S. Fed. Trade Comm’n, FTC Announces Settlements with Four Companies 
Related to Allegations they Deceived Consumers over Participation in the EU-Privacy Shield, (Dec. 3, 2019) 
https://www.ftc.gov/news-events/press-releases/2019/12/ftc-announces-settlements-four-companies-related-
allegations-they.  
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and deceptive practices under the FTC Act.99 The only meaningful action the FTC took was against 
GeneLink in 2014 for health-related claims not supported by the evidence, and data security 
practices that rose to the level of unfair and deceptive.100 The Health Breach Notification Rule 
requires businesses not covered by HIPAA to notify customers if there is a breach of “unsecured, 
individually identifiable electronic health information.”101 The rule applies to a vendor of personal 
health records who maintains an online service that allows consumers to share, organize, and 
manage identifiable health information drawn from multiple sources e.g. maintaining medical 
records in a physician’s mobile application to upload changes in weight, blood pressure, and 
diet.102 
 DTC-GTCs will be subject to the FTC’s oversight regarding compliance with the EU-
Privacy Shield and data security practices. However, the health breach notification rule does not 
apply to DTC-GTCs because they are not a vendor, i.e., they do not maintain a service for patients 
to access and upload changes to medical records. 
7. Common Rule for Clinical Research  
 The Common Rule mandates that research involving FDA-regulated products or research 
conducted or supported by a federal agency must seek Institutional Review Board (“IRB”) 
approval before conducting studies involving human subjects.103 Research projects limited to 
 
99 Fed. Trade Comm’n Act of 1914 15 U.S.C. §§41-58 (2018). 
100 In Re GeneLink, Inc. & Foru Int’l Corp., No. 112-3095 U.S. Fed. Trade Comm’n (Jan. 7, 2014).  
101 Health Breach Notification Rule, U.S. Fed. Trade Comm’n.  
102 Id.  
103 Ernest D. Prentice & Bruce G. Gordon, Institutional Review Board Assessment of Risks and Benefits Associated 
with Research, 2 NAT’L BIOETHICS ADVISORY COMM’N, ETHICAL & POL’Y ISSUES IN RESEARCH 
INVOLVING HUMAN PARTICIPANTS, 1 (2001). 
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publicly available data are not subject to IRB review.104 Researchers do not need prior IRB 
approval for aggregated and de-identified genetic information.105  
 DTC-GTCs have added research opportunities where customers can share their genetic 
information for use in research (23andWe, and Navigenics).106 23andMe’s research division, 
called 23andWe, is structured to investigate the causes of diseases and develops drugs and 
treatments accordingly.107 23andWe incorporates a large pool of samples from consumers 
participating in standard test kits and establishes location-based clinical trials.108 Research 
participants of the clinical trials contribute their genetic information and health background 
prompted by online surveys.109 Other DTC-GTCs like Navigenics “believe in … helping further 
scientific and medical research.”110 The company may use consumers' genetic data to “discover 
and validate associations between certain genetic variations and certain health conditions or 
traits.”111 Navigenics findings may be published “without disclosing Genetic Data sufficient to 
uniquely identify [participants].”112 deCODEme also invites its customers to participate in research 
activities.113 Private-based DTC-GTCs are not required to seek IRB approval for research projects 
as they do not receive federal funding and are not subject to federal regulations.  
 
104 45 CFR 46.102(b)(4). 
105 45 CFR 46.102(f) biological specimens or private information is identifiable when it can be linked directly or 
indirectly to a specific individual, when this information is obtained for research purposes it constitutes as human 
subjects research. See also U.S. DEPT. OF HEALTH AND HUMAN SERVICES, OFFICE FOR HUMAN 
RESEARCH PROTECTIONS, GUIDANCE ON CODED PRIVATE INFORMATION OR SPECIMENS USE IN 
RESEARCH, (2008) https://www.hhs.gov/ohrp/regulations-and-policy/guidance/research-involving-coded-private- 
information/index.html. 
106 45 CFR 46.102(b)(4). 
107 Consent Document, 23andMe, https://www.23andme.com/about/consent.  
108 Research Revolution, 23andMe, https://www.23andme.com/researchrevolution.  
109 Consent Document, supra note 107.  
110 Privacy Policy, Navigenics, http://www.navigenics.com/visitor/what_we_offer/our_policies/privacy.  
111 Id. 
112 Id.  
113 Terms of Use, deCODEme, http://decodeme.com/terms-of-use.  
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B. State Privacy Laws 
 Most states have enacted legislation to prohibit insurers from collecting or using genetic 
information to discriminate.114  
1. California Consumer Privacy Act (“CCPA”) 
 The CCPA provides California residents with the right to (1) know what personal data115 
is collected about them; (2) be notified of sale or disclosure of personal data; (3) object to the sale 
of personal data; (4) access their data; (5) freedom to exercise their rights without fear of 
discrimination; and (6) request a business to delete any acquired personal data.116 CCPA applies 
to any organization that does business in California and has either (1) annual gross revenues greater 
than $25 million; (2) earns more than half of its revenue from selling consumers' personal 
information or (3) maintains the personal information of 50,000 or more consumers.117 
Corporations are required to (1) designate methods for submitting data access requests;118 (2) 
update privacy policies to include a description of residents’ rights;119 and (3) the company’s 
website must have an opt-out link on the homepage to “Do Not Sell My Personal Information.”120 
Companies who do not comply may be fined up to $7,500 for each intentional violation, $2,500 
 
114 NAT’L CONFERENCE OF STATE LEGISLATORS, STATE GENETIC PRIVACY LAWS, 
http://www.ncsl.org/research/health/genetic-nondiscrimination-in-healht-insurance-laws.aspx [hereinafter State 
Privacy Laws]. 
115 Cal. Civ. Code §1798.140; Cal. Civ. Code §1798.185(k)(2). Personal data is information that “relates to, describes, 
is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular 
consumer or household such as a real name, alias, postal address, unique personal identifier, IP address, email address, 
account name, SSN #, or other similar identifiers. Personal data includes biometric information which means an 
individual’s physiological, biological or behavioral characteristics, including an individual’s DNA, that can be used, 
singly or in combination with each other or with other identifying data, to establish individual identity. Publicly 
available does not mean biometric data collected by a business about a consumer without the consumer’s knowledge. 
Publicly available also does not include consumer information that is de-identified or aggregated.  
116 Title 1.81.5 The California Consumer Privacy Act of 2018 § 1798.110.  
117 Id.  
118 Cal. Civ. Code §1798.130(a).  
119 Cal. Civ. Code §1798.135(a)(2).  
120 Cal. Civ. Code §1798.102.  
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for each unintentional violation, and statutory damages between $100-$750 per California resident 
if they become victims of data theft or breach.121 
 23andMe is subjected to CCPA because it maintains personal information, including 
biometric data of more than 50,000 consumers, has annual gross revenue over $25 million, and 
conducts business in California.122 Because not every aspect of 23andMe’s business takes place 
outside of California, CCPA restricts the business’ ability to collect or sell consumers’ personal 
information. Anything de-identified or aggregated under CCPA is not considered publicly 
available and is subject to the Act's compliance.  
2. Other State Laws and Regulations 
States’ privacy protections vary.123 Some states mandate individual access to personal 
genetic information.124 Genetic information is defined as “personal property” in Alaska, Colorado, 
Florida, Georgia, and Louisiana.125 Likewise, Rhode Island and Washington require companies to 
receive written authorization to disclose genetic information.126 Forty-seven states prohibit the use 
of genetic information to determine rates of insurance eligibility.127 Twenty-seven states require 
informed consent for a third party to perform or request a genetic test or to obtain genetic 
information.128 Eighteen states have specific penalties for violating genetic privacy laws.129 One 
state extends personal property rights to DNA samples.130  
 
121 Cal. Civ. Code §1798.150, 155.  
122 23andMe 10K ($475 million annual gross revenue and headquarters is located in Mountainview, California).  
123 State Privacy Laws, supra note 114. 
124 Id. 
125 Id. 
126 Id. 
127 Id. 
128 Id. 
129 Id. 
130 Id. 
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C. International Transparency Standards – General Data Protection Regulation 
 In May 2018, the European Union (“EU”) launched the General Data Protection Regulation 
(“GDPR”) to protect the “fundamental rights and freedoms of natural persons and their right to the 
protection of personal data.”131 GDPR applies to all companies, not just healthcare providers or 
insurance companies. GDPR defines personal health data to include: 
“all data pertaining to the health status of a data subject which reveal information 
relating to the past, current or future physical or mental health status of the data 
subject. This includes information about the natural person collected in the course 
of the registration form, or the provision of, health care services as…a number, 
symbol or particular assigned to a natural person to uniquely identify the natural 
person for health purposes; information derived from the testing or examination of 
a body part or bodily substance, including from Genetic Data and biological 
samples; and any information on, for example, a disease, disability, disease risk, 
medical history, clinical treatment or the physiological or biomedical state of the 
data subject independent of its source, from a physician or other health professional, 
a hospital, a medical device or an in vitro diagnostic test.”132 
GDPR is legally binding for United States businesses with global operations, international 
sites, or even remote workers.133  The GDPR defines genetic data as personal data  
“relating to the inherited or acquired genetic characteristics of a natural person 
which result from the analysis of a biological sample from the natural person in 
question, in particular chromosomal, deoxyribonucleic acid (DNA) or ribonucleic 
acid (RNA) analysis, or from the analysis of another element enabling equivalent 
information to be obtained.”134 
Any test results acquired from DTC-GTs create genetic data, and as such, any testing companies 
that function in the EU must adhere to GDPR for personal data and consent. Under GDPR, 
 
131 Art. 1 GDPR Subject-matter and objectives.  
132 Recital 35 EU General Data Protection Regulation [emphasis added].  
133 Art. 3 GDPR Territorial Scope. This Regulation applies to the processing of personal data in the context of the 
activities of an establishment of a controller or a processor in the Union, regardless of whether the processing takes 
place in the Union or not. This Regulation applies to the processing of personal data of data subjects who are in the 
Union by a controller or processor not established in the Union, where the processing activities are related to: (1) 
the offering of goods or services, irrespective of whether a payment of the data subject is required, to such data 
subjects in the Union; or (2) the monitoring of their behavior as far as their behavior takes place within the Union. 
This Regulation applies to the processing of personal data by a controller not established in the Union, but in a place 
where Member State law applies by virtue of public international law. [emphasis added]. 
134 Recital 34 Genetic Data, General Data Protection Regulation.  
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processing of personal data requires approval from the data subject or an expressed provision of 
law.135 GDPR also requires the right of EU citizens to be informed about the storage and use of 
their data.136 A company must immediately notify individuals when obtaining their data.137  
 Companies like 23andMe and Ancestry that are global companies offering consumer health 
services would be considered controllers under the GDPR. As a controller, these testing companies 
are responsible for maintaining the protection of personal data through consent and processing 
requirements. 
D. Future of Privacy Forum Best Practices 
 The Future of Privacy Forum established voluntary privacy best practices for consumer 
genetic testing services.138 Companies’ privacy practices are required to maintain complete 
transparency about how genetic data is collected, used, shared, and retained.139 The privacy 
disclosure must include publicly posting a high-level summary of privacy protections easily 
accessible to consumers.140 Companies must have a separate express consent for the transfer of 
genetic information to third parties and are banned from sharing the information with employers, 
 
135 Recital 32 Conditions for Consent, General Data Protection Regulation; See also Art 7. GDPR Conditions for 
Consent: (1) freely given on a voluntary basis; (2) must notify fata subject of controller’s identity, what of data will 
be processed, how it will be used and the purpose of the processing operation; (3) must inform data subject of their 
right to withdraw consent at any time; and (4) consent requires a clear statement or affirmative act. 
136 Art. 12 GDPR Transparent information, communication and modalities for the exercise of the rights of the data 
subject; Art. 13 GDPR Information to be provided where personal data are collected from the data subject; Art. 14 
GDPR Information to be provided where personal data have not been obtained from the data subject. [hereinafter 
Information Transparency].  
137 Information Transparency, supra note 136. The controller’s obligation to inform includes his identity, the contact 
data of the Data Protection Officer (if available), the processing purposes and the legal basis, any legitimate interests 
pursued, the recipients when transmitting personal data, and any intention to transfer personal data to third countries. 
The right to be informed also includes information about the duration of storage, the rights of the data subject, the 
ability to withdraw consent, the right to lodge a complaint with the authorities and whether the provision of personal 
data is a statutory or contractual requirement.  
138 FUTURE OF PRIVACY FORUM, PRIVACY BEST PRACTICES FOR CONSUMER GENETIC TESTING 
SERVICES, (July 31, 2018) https://www.healthlawadvisor.com/files/2019/06/Privacy-Best-Practices-for-Consumer-
Genetic-Testing-Services-FINAL.pdf. [hereinafter Future of Privacy Forum]. 
139 Id. 
140 Id.  
21
Missel: Direct-to-Consumer Genetic Testing: Maintenance of Individual Pri
Published by eRepository @ Seton Hall, 2020
Missel 21 
 
insurance companies, educational institutions, and government agencies without consent unless 
required by law.141 However, DTC-GTCs are not required to participate in the future of privacy 
forum, and only a select number of companies are supporters of the best practices, including 
23andMe, Ancestry, MyHeritage, Helix, Habit, African Ancestry, and Living DNA.142 If a 
company’s policy conflicts with the best practices, the forum will remove the company as a 
supporter.143 
E. Genetic Testing Companies’ Privacy Policies  
 Both 23andMe and Ancestry present customers with two documents upon purchasing a test 
kit. The first document the companies present are the terms and conditions that include a privacy 
statement. The second document is an informed consent document. Customers must accept the 
terms and conditions before they can buy a test kit from the company. The informed consent 
document is presented to consumers when they are registering their test kit as it relates to additional 
research projects run by the company, e.g., 23andWe. Both 23andMe and Ancestry have a history 
of sharing anonymized consumer data with third parties.  
1. 23andMe 
23andMe’s website contains very detailed privacy statements, which address how the 
company collects, manipulates, and protects genetic information.144 The website defines personal 
information as “information that can be used to identify a user either alone or in combination with 
other information.”145 Personal information is broken down into genetic information (data 
 
141 Id.  
142 Id.  
143 Id. FamilyTreeDNA was removed as a supported following their agreement with the FBI.   
144 Privacy Statement, 23andMe, https://www.23andme.com/about/privacy/; Terms of Service, 23andMe, 
https://www.23andme.com/about/tos.  
145 Id.  
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generated by processing a user’s DNA sample), registration information (name, email address, etc. 
used to create an account or purchase test kits), and self-reported information (user’s response to 
surveys).146  
23andMe requires users to complete two informed consent documents.147 The main 
research consent document includes that 23andMe can use individual-level genetic information 
and self-reported information internally.148 For third party research purposes, the information must 
be de-identified and not linked to registration information.149 The company also provides an 
individual-level data sharing consent form which includes the same uses as above and that 
23andMe may share de-identified individual-level genetic information and self-reported 
information with select third party research contributors.150 The document also allows users to 
withdraw consent by changing their consent status in their account settings.151 However, once data 
is shared with third parties, it will not be withdrawn.152 23andMe also does not state how it protects 
the confidentiality of the shared information or how it prohibits attempts to re-identify individuals. 
23andMe is also committed to compliance with GDPR.153 
23andMe maintains different levels of data sharing.154 Users’ aggregate data, individual-
level genetic information, and self-reported information may be shared as specified in the consent 
document.155 23andMe may share with both commercial third parties, and non-profits 
 
146 Id.  
147 Research Consent Document, 23andMe, https://www.23andme.com/about/consent/; Terms of Service, supra note 
144. 
148 Id.  
149 Research Consent Document, supra note 147.  
150 Id. 
151 Id. 
152 Id. 
153 Data Protection, 23andMe, https://www.23andme.com/gdpr/?vip=true 
154 Id. 
155 Id. 
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aggregated156 genetic and self-reported data.157 De-identified genetic information may be 
published in peer-review journals and other research funded by the federal government (NIH) 
conducted by 23andMe.158 23andMe research may be sponsored, conducted on behalf, or in 
collaboration with third parties (foundations, academic institutions and pharmaceutical 
companies).159  
2. Ancestry DNA 
 Ancestry DNA states customers' genetic data will be used correctly for: “genetic and 
genealogical research, including population health and ethnicity-related analyses, and not to 
provide you individual medical or diagnostic purposes.”160 Put another way, Ancestry uses genetic 
information to provide customers with ancestry results and identify relatives based on similar DNA 
molecular markers. The company also states that consumer data is de-identified to make 
discoveries in population genetics.161 Ancestry DNA’s privacy policy contains three significant 
provisions: “(1) the perpetual, royalty-free, worldwide license to use your DNA; (2) the warning 
that DNA information may be used against ‘you or a genetic relative’; and (3) your waiver of legal 
rights.”162 These provisions give a written warning to Ancestry customers but are embedded in 
“click-wrap” (requiring the user to “agree” upon ordering the kit, which most consumers consent 
 
156 Privacy Statement, supra note 144. “It has been stripped of registration information and combined with data from 
other users to minimize the possibility of exposing individual-level information.” Aggregate data is information 
combined with other users and analyzed or evaluated as a whole with no specific individual identified. e.g., 30% of 
our female users share a particular genetic trait. Individual information is information about a single individual’s 
genotypes, diseases or other traits/characteristics.  
157 Id. 
158 Id. “If you choose to consent to participate in 23andMe Research, 23andMe researchers can include your de-
identified genetic information and self-reported information in a large pool of customer data for analyses aimed at 
making scientific discoveries.” 
159 Id.  
160 Privacy Statement, Ancestry, https://www.ancestry.com/cs/legal/privacystatement 
161 Id.  
162 Id.  
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to without reading the entire agreement) or “browser-wrap” (implies consent by use of the website) 
agreements.163 Furthermore, Ancestry maintains ownership of the customers’ DNA in 
perpetuity.164 
3. Personal Genome Project 
Harvard School of Medicine’s Personal Genome Project (“PGP”) publishes all information 
submitted by a participant, including physical traits, medical information, and photographs on 
PGP’s public website along with genetic information.165 While individuals interested in 
participating must submit to a rigorous pre-enrollment questionnaire and consent process, family 
members do not.166 Once PGP releases the information, neither PGP nor the participant can control 
who has access, can make copies, or use the information.167 This poses a concern for the individual 
as well as family members because “anyone with sufficient knowledge and resources” could use 
the data to claim a participant is predisposed to a disease, or they are related to criminals.168 
4. Burying Privacy Disclaimers in Terms and Conditions  
 While genetic testing companies claim to have privacy protections surrounding genetic 
information, most of the policies follow a take it or leave it approach. If individuals do not consent 
to the privacy statements, they cannot obtain a DTC-GT. Consumers consent to collecting risk 
information and disclosure of results by clicking “yes” on a dialogue box. The mere click should 
not be considered informed consent unless consumers spend the time to read the disclosure in its 
 
163 Andelka M. Phillips, Reading the Fine Print When Buying Your Genetic Self Online: Direct-to-Consumer Genetic 
Testing Terms and Conditions, 36 NEW GENETICS & SOC’Y 278 (2017). 
164 Id.  
165 Personal Genome Project, Consent Form: Personal Genome Project § X:10.1 (2010), 
http://www.personalgenomes.org/consent/PGP_Consent_Approved03312010.pdf [hereinafter Full Consent]. 
166 Personal Genome Project, Consent Form: Eligibility Screening for the Personal Genome Project § 1 (2010), 
available at http://www.personalgenomes.org/consent/PGP_MiniConsent_Approved03312010.pdf [hereinafter Mini 
Consent]; How It Works, Personal Genome Project. http://www.personalgenomes.org/howitworks.html.  
167 Id.  
168 Full Consent, supra note 165, at § VII:7.1(a)(iii).  
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entirety.169 Consenting to terms and conditions by clicking on an “accept” or “yes” dialogue box 
is now very commonplace given the bombardment of consumers downloading applications and 
routine operating system updates, which most people consent to without reading the statements.170 
If customers of DTC-GTs operate reading the permission in the same way that they consent to 
system updates, they are genuinely not informed. Companies can bury privacy information, the 
length samples will be kept, and means of selling genetic information in the “informed consent” 
without customers knowing how their genetic information is being stored and manipulated.  The 
gaps in privacy regulations cause consumers to agree to security protections absentmindedly and 
as routine as clicking through website terms and conditions. 
IV. Gaps in Existing Consumer Protection 
 Despite the existing federal and state safeguards, some of these laws still do not adequately 
address privacy issues and consumer protection related to genomic data. Consumers may believe 
that HIPAA protects their information yet, HIPAA does not cover DTC genetic testing companies 
as detailed above. Both CLIA and the FDA continue to have a regulatory gap with no oversight to 
protect individual privacy when analyzing DTC-GTs. The FTC has done very little to enforce 
companies’ privacy compliance. Nevertheless, privacy concerns persist with the sharing of de-
 
169 Joel R. Reidenberg et al., Privacy Harms and the Effectiveness of the Notice and Choice Framework, 11 I/S: J.L. 
& POL’Y FOR INFO. SOC’Y 485 (2014). 
170 Tompkins v. 23andMe, Inc., 840 F.3d 1016, 1020 (9th Cir. 2016) (A customer interested in obtaining the genetic 
test must visit the 23andMe website to purchase an online DNA testing kit. When purchasing the kit, the customer can 
click on a link to the company's Terms of Service that was available at the bottom of the webpage. However, the 
customer is not required to read or click through the terms before making a purchase. After receiving the kit, the 
customer returns to the website to create an online account with 23andMe to register the DNA kit. At this stage, and 
in order to proceed to use the genetic testing service, a customer has to click on a box indicating agreement to the 
Terms of Service. The Terms of Service is a multipage agreement which states that it constitutes the entire agreement 
between 23andMe and its customers.) 
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identified information because, with emerging technology, third parties may misuse this 
information and is not truly de-identified.171  
A. Potential for Third-Party Misuse of Data 
 Whole exome and whole-genome sequencing, as mentioned above, rely on sharing data by 
looking at the genomic sequences of large populations of people. However, there are concerns that 
this technology will affect individual privacy with the increased number of individuals who can 
access the data leading to misuse or breach.  The misuse or breach of data stems from recent events 
involving electronic health record breaches.172 
 Several state statutes require the preservation of DNA samples.173 Preservation of the 
sample allows future testing of the sample when new technologies become available.174 The 
preservation of the sample also raises concerns about physicians’ misuse of consumer health 
information.175 However, physicians are HIPAA covered entities and cannot share PHI for 
marketing tactics unless they fall into a HIPAA exception.176 
Conversely, DTC-GTCs may misuse consumer health information for marketing since 
there are no regulatory requirements in place to govern the use of personal data. While physicians 
cannot manipulate genetic information, DTC-GTCs are not HIPAA covered entities, and no other 
federal or state laws prohibit testing companies' use of genetic information for promotional 
 
171 Future Privacy Forum, supra, note 138.  
172 W.W. Koczkodaj, et al., Electronic Health Record Breaches as Social Indicators, 141 SOC. INDIC. RES. 861, 
861–871 (2019). 
173 See ALA Code § 36-18-22 (Supp. 1994); CAL Penal Code § 290.2 ; N.C Gen Stat. §15A-266.5(b); VA Code Ann. 
§ 19.2-310.3. 
174 Id.  
175 C. Critchley et al., Public reaction to direct-to-consumer online genetic tests: Comparing attitudes, trust and 
intentions across commercial and conventional providers, 24 PUBLIC UNDERST. SCI. 731, 731–750 (2014). 
176 HIPAA, supra, note 64.  
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purposes. Testing companies governed by GDPR cannot process, store, or share genetic 
information with third parties without the express permission of the individual.  
 There is also the potential for misuse of data in what is being called “DNA theft.”177 There 
is an increased risk that “third parties may attempt to collect and analyze anyone’s DNA without 
consent.”178 Since DTC-GTCs only require a customer to accept the company’s terms and 
conditions before purchasing a kit, individuals may submit another person’s sample without their 
knowledge or consent. Public databases like PGP and GEDMatch could also result in false claims 
of a criminal relationship or disease predisposition if someone altered and republished the same 
data obtained from DTC-GTCs. Someone could also make synthetic DNA from the public 
database and plant it at a crime scene to implicate a person in a crime. 
B. Using Molecular Markers to De-Anonymize Genetic Data 
 The nature of genetics is information taken from one person’s genetic composition that 
may be shared with biological siblings and offspring.179 For this reason, genetic information is 
considered sensitive, primarily since it can also determine predisposition to a gene that could affect 
an individual or a family.180 Genetic data can be de-anonymized by genetic markers tied to specific 
physical traits like hair and eye color.181 The physical characteristics can be cross-referenced with 
publicly available data to identify whom the DNA belongs to.182 
 
177 Elizabeth E. Joh, DNA Theft: Recognizing the Crime of Nonconsensual Genetic Collection and Testing, 91 B.U. L. 
Rev. 665 (2011); see also Eriq Gardner, Gene Swipe: Few DNA Labs Know Whether Chromosomes Are Yours or If 
You Stole Them, 97-AUG A.B.A. J. 50 (2011).  
178 Id.  
179 Genetic Analysis, supra, note 2, at 4.  
180 Id.  
181 Id. at 6-7.  
182 Genetic Testing, supra, note 22.  
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 People believe a “robust anonymization assumption” that by removing specific identifiers, 
the individual would remain anonymous.183 The NIH removed some genetic data from publicly 
available websites184 following a study that identified a single individual’s DNA contribution from 
a pool of a thousand samples.185 Another example deals with the Massachusetts Group Insurance 
Commission’s removal of explicit identifiers where researchers were able to de-identify patient 
records and identify the governor.186 As previously discussed, SNPs are useful in DTC-GTs 
because they correspond to both non-clinical and clinical traits. A study in 2004 determined that 
thirty SNPs can be used to identify a single person out of the millions of SNPs analyzed in a genetic 
test.187 Someone who has access to both anonymized genetic data and public data may be able to 
de-anonymize the data and identify an individual with a small set of SNPs. Scientists can also 
determine a person’s surname by studying the short tandem repeats on the Y chromosome and 
linking that with publicly available information.188 
 Any form of genetic information sharing through the public domain or for research (DTC-
GTCs information sharing with third-parties and non-profit research institutions) creates the 
possibility that someone will access the data and re-identify the set. As mentioned in PGP’s 
overview, this poses a concern for the individual as well as family members. The gaps in protection 
implicate autonomy and privacy for family members who do not want to share their genetic 
information or know risk facts that their relatives’ DNA might reveal. 
 
183 Paul Ohm, Broken Promises of Privacy: Responding to the Surprising Failure of Anonymization, 57 UCLA L. Rev. 
1701, 1706 (2010). [hereinafter Broken Promises of Privacy]. 
184 Jennifer Couzin, Whole-Genome Data Not Anonymous, Challenging Assumptions, 321 SCIENCE 1278, 1278 
(2008).  
185 Nils Homer et al., Resolving Individuals Contributing Trace Amounts of DNA to Highly Complex Mixtures Using 
High-Density SNP Genotyping Microarrays, 4 PLoS Genetics 1, 7 (2008). .  
186 Broken Promises of Privacy, supra note 183, at 1719-20.  
187 Zhen Lin et al., Genetics, Genomic Research & Human Subject Privacy, 305 SCIENCE 183, 183 (2004).   
188 Melissa Gymrek et al., Identifying Personal Genomes by Surname Inference, 339 SCIENCE 321, 321-24 (2013).   
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C. Access to Genetic Information by Life, Disability, and Long-Term Care Insurance   
 The dangers of misinterpretation of genetic information attribute to the fears of gene 
testing, genetic discrimination, and insurance coverage. For instance, genetic tests could 
previously lead to discrimination by insurance companies in terms of health care coverage.189 
Though under GINA genetic discrimination is prohibited by corporations and health insurers, 
genetic tests also bring about concerns for life, disability, and long-term care insurance 
coverage.190 
Genetic test results have led to manipulation by life, disability, and long-term care 
insurance companies. Companies that offer these policies have the right to request genetic test 
results when making decisions about coverage and insurance premiums.191 Insurance companies 
then use this information to place people into groups based on risks. Specifically, if a genetic test 
was shown as part of the patient’s medical history, insurance companies could use this information 
to determine coverage for life and disability insurance. 
Nevertheless, just because someone has a predisposition to something, there is no 
guarantee they will manifest the disease during their insurance period. If the individual did not 
disclose the test results, they would be evaluated as less risky and have slightly better premiums. 
Additionally, physicians include genetic results from tests they order into the patient’s medical 
record, and the insurance company will most likely have access to that information. Given the 
consent forms DTC-GTCs require consumers to submit for research purposes, DTC-GT results 
hopefully are secure from the insurance companies' access. Due to genetic discrimination in these 
 
189“Fears of genetic discrimination by employers and insurance companies continue to influence decisions regarding 
submission to genetic testing and participation in certain forms of genetic research.” PHYLLIS GRIFFIN EPPS, 
GENETIC DISCRIMINATION,  2 ENCYC. OF BIOETHICS,  (3rd ed. 2004).  
190 Id. 
191 Genetic Testing, supra note 22, § Can Results Affect Insurance? 
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types of insurance, people may avoid genetic tests for fear that taking the test or getting a positive 
result could affect their coverage. 
V. Consideration of Mechanisms to Maintain Individual Privacy  
 The United States needs new genetic privacy laws to protect individual privacy, related 
explicitly to DTC-GTs. Providing privacy protections should be maintained on a federal level, not 
on a state-by-state basis. State-based privacy protections would not solve consumers’ privacy 
concerns, as some states may allow sharing of genetic information that could link a family member 
who does not want their information shared from a state with more stringent privacy protections. 
The federal government should focus on either applying a standard like GDPR or modify what is 
classified as a HIPAA covered entity. The main difference between the structure of GDPR and 
HIPAA is that GDPR defines entities based on ownership of data, and HIPAA defines entities 
based on the function of the organization. 
A. Expansion of HIPAA and GINA 
 Congress should amend HIPAA to include genetic testing companies as covered entities 
under HIPAA. Most consumers assume their genetic information is stored and protected following 
HIPAA regulations. However, as discussed above, that is not the case. HIPAA does not govern 
the activities of genetic testing companies because they are not considered covered entities or 
business associates. Consumers must then agree to privacy and security protections through click-
through policies. If genetic testing companies were classified as covered entities, because they 
already transmit information in an electronic form, they could not share consumers’ genetic 
information. A criticism to this approach, is that by preventing information sharing it halts 
scientific growth and expansion. Anonymized consumer genetic information may be helpful in 
identifying diseases or genetic irregularities in various communities through population genetics 
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as researchers can have access to large sample sizes. However, the drawbacks to expanding HIPAA 
do not outweigh protecting consumer privacy interests, as individuals can still elect to have DTC-
GTCs sell their data.  
 Congress should also expand GINA to include protection of all genetic data regardless of 
the source of that information. In conjunction with the HIPAA expansion, this would help to 
ameliorate some of the effects of data misuse and insurance discrimination while boosting 
consumer participation in buying test kits. The FDA and CLIA could also regulate DTC-GTC’s 
commercial test kits in the same manner that they regulate LDTs ordered by physicians. The 
proposed changes would fill in some gaps, but it would not prevent re-identification from public 
domain uploads.  
B. Protection Against Re-identification and Restricting Research  
 A primary unintended consequence of data sharing, DTC-GTs, and genetic research is the 
misuse of data and de-anonymization. Congress could expand the Common Rule to include all 
research projects, whether implemented by private companies or those under federal 
grants/regulations. Then DTC-GTCs would have to draft research proposals and consent 
documents for IRB approval before sharing genetic information with third parties and 
pharmaceutical companies. However, DTC-GTCs are unlikely to support this change because it 
may prevent research opportunities and minimize the profit DTC-GTCs can receive for selling 
genetic data to pharmaceutical companies.  
 Another solution is to have consumers maintain ownership of their data. In turn, genetic 
testing companies would provide customers with a complete readout of their genome that the 
individual could anonymously share with whomever at their choosing, including third-party 
pharmaceutical companies interested in marketing drugs to individuals based on genetic markers. 
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This structure is like GDPR right to data portability in which subjects have the right to receive and 
transmit their data with whom they see fit without any hindrance.192 However, this may also lead 
to re-identification if the information ends up in the wrong hands. Furthermore, data portability 
requirements would be inapplicable to PGP’s structure because one of its goals is unrestricted, 
public sharing.  
C. GDPR-like Regulatory Framework  
 The best approach is to apply a federal privacy standard similar to how the EU structured 
the GDPR by requiring notification of when personal data is obtained and how the records are 
processed. GDPR processing requirements would still allow the federal government to access 
personal data relating to criminal convictions or offenses.193 The GDPR fines194 also provide 
companies incentives to maintain compliance with the regulations. Researchers that share 
biological samples that contain genetic information would be held to personal data protection 
standards. This approach would require researchers to notify individuals when biological samples 
are processed and obtain express consent from the individuals before processing information and 
sharing it with third parties. The GDPR also requires data to be destroyed once the relationship 
between the controller and the processor ends. By implying this requirement, it limits the ability 
to aggregate and retain personal data for future use, which in turn can prevent the potential for 
third-party misuse of data and reduce/eliminate de-anonymizing genetic data. While this may not 
 
192 Art. 20 GDPR Right to Data Portability.  
193 Art. 10 GDPR Processing of personal data relating to criminal convictions and offences. Processing of personal 
data relating to criminal convictions and offences or related security measures based on Article 6(1) shall be carried 
out only under the control of official authority or when the processing is authorized by Union or Member State law 
providing for appropriate safeguards for the rights and freedoms of data subjects. Any comprehensive register of 
criminal convictions shall be kept only under the control of official authority. 
194 If a company does not maintain records of processing activities and/or does not provide a complete index to 
authorities, they are subject to fines according to Art. 83(4)(a) of the GDPR. The possible fines can be up to 10 million 
euros or 4% of their annual turnover. This total is, as a rule, only assessed by the authorities in exceptional cases. For 
this, the authorities are encouraged, as set forth in recital 13, “to take account of the specific needs of micro, small and 
medium-sized enterprises in the application of this Regulation.” 
33
Missel: Direct-to-Consumer Genetic Testing: Maintenance of Individual Pri
Published by eRepository @ Seton Hall, 2020
Missel 33 
 
be a perfect solution, it gives consumers more control over their personal information even though 
it may dissuade companies from selling or utilizing consumers’ data.  
VI. Conclusion  
 DTC-GTC’s need to implement robust privacy and security programs to mitigate the gaps 
in regulation with improved data storing and sharing security. Currently, there are no precise 
regulatory mechanisms in place to protect patient autonomy and individual privacy. Because so 
much can be gained from DTC-GTs and genetic research, participation should be protected where 
possible. At a minimum, Congress should expand HIPAA and GINA to cover all genetic 
information no matter where the data is obtained. Nevertheless, the best approach is to enact a 
GDPR-like regulatory framework that would promote individual autonomy and privacy while 
fostering a collaborative research environment.  
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